Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003)

Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003)

Abstract Aim The aim is to report the long‐term outcomes of preoperative cisplatin and fluorouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squamous cell carcinoma (ESCC). Previously, this trial showed that DCF is associated with prolonged recurrence‐free survival (RFS). M...

Full description

Bibliographic Details
Main Authors: Keijiro Sugimura, Makoto Yamasaki, Takushi Yasuda, Masahiko Yano, Motohiro Hirao, Kazumasa Fujitani, Yutaka Kimura, Hiroshi Miyata, Masaaki Motoori, Atsushi Takeno, Osamu Shiraishi, Tomoki Makino, Takayuki Kii, Koji Tanaka, Taro Satoh, Masaki Mori, Yuichiro Doki
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Annals of Gastroenterological Surgery
Subjects:
esophageal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
Online Access:https://doi.org/10.1002/ags3.12388

Internet

https://doi.org/10.1002/ags3.12388

Similar Items